A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2016
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LIBERATE
- Sponsors Hanmi Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 19 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by European Clinical Trials Database record.
- 09 Jun 2015 Interim results in 86 patients presented at the 75th Annual Scientific Sessions of the American Diabetes Association.